From Bench to Breath: Zongertinib’s Journey Toward the First Oral HER2‑Targeted Therapy

Podcast | English | 2025 | 41 Min

Create Account

Cost

$0.00

Credit

No Credit Offered

In this episode of Lung Cancer Considered, host Dr. Narjust Florez discusses HER2 non-small cell lung cancer and the recently approved zongertinib. Dr. Ibiayi Dagogo-Jack and Dr. Gerrina Ruiter join the conversation to help review the data and discuss its place in the management of patients with HER2-positive NSCLC.

Podcast Host:

Narjust Florez, MD, Associate Director of the Cancer Care Equity Program and Thoracic Medical Oncologist, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School, Boston, MA, USA

Podcast Guests:

Ibiayi Dagogo-Jack, MD, Thoracic Medical Oncologist, Massachusetts General Hospital, Associate Professor of Medicine, Harvard Medical School, Boston, MA, USA
Gerrina Ruiter, MD, PhD, Pulmonologist, Department of Thoracic Oncology, Department of Phase 1 Studies, Antoni van Leeuwenhoek - Netherlands Cancer Insitute, Amsterdam, The Netherlands